DE-ESCALATION OF SURGERY IN BREAST CARCINOMA PATIENTS FOLLOWING NEOADJUVANT CHEMOTHERAPY
DOI:
https://doi.org/10.71000/rg5t8v13Keywords:
Breast Carcinoma; Breast-Conserving Surgery; Clinical Stage; Mastectomy; Neoadjuvant Chemotherapy; Surgical De-escalation; Treatment Response.Abstract
Background: Breast carcinoma remains a major cause of cancer-related morbidity among women, particularly in settings where patients often present with advanced disease. Neoadjuvant chemotherapy has become an important treatment approach because it can reduce tumor burden before surgery and increase the feasibility of breast-conserving procedures. Evaluating its role in surgical de-escalation is clinically relevant for improving oncological safety, cosmetic outcomes, recovery, and patient-centered breast cancer care.
Objective: To evaluate the role of neoadjuvant chemotherapy in facilitating surgical de-escalation among patients with breast carcinoma.
Methods: This comparative observational study was conducted in the Department of Surgery, Khyber Teaching Hospital, Peshawar, from 1 December 2025 to 31 May 2026. A total of 213 adult female patients with histologically confirmed breast carcinoma who received neoadjuvant chemotherapy followed by definitive surgery were included through consecutive sampling. Data regarding age, body mass index, symptom duration, laterality, clinical stage, histopathological type, tumor grade, response to neoadjuvant chemotherapy, and type of surgery were collected using a structured proforma. Data were analyzed using SPSS version 26.0. Associations were assessed using Chi-square or Fisher’s exact test, and binary logistic regression was used to identify predictors of breast-conserving surgery. A p-value of <0.05 was considered statistically significant.
Results: The mean age was 41.5 ± 10.7 years, and the mean body mass index was 24.5 ± 3.1 kg/m². Most patients were aged ≤40 years (55.4%), presented within 3 months of symptoms (57.7%), and had Stage III disease (39.9%). Invasive ductal carcinoma Grade II was the most common histological type (57.3%), followed by invasive ductal carcinoma Grade III (41.3%). Complete response to neoadjuvant chemotherapy was observed in 28.6%, partial response in 58.2%, and no response in 13.1%. Breast-conserving surgery was performed in 57.3%, while 42.7% underwent mastectomy. Complete response was strongly associated with breast-conserving surgery, as 78.7% of complete responders underwent breast conservation compared with 14.3% of non-responders. On regression analysis, complete response, earlier clinical stage, younger age, shorter symptom duration, and Grade II tumors were independently associated with breast-conserving surgery.
Conclusion: Neoadjuvant chemotherapy supported surgical de-escalation by increasing the feasibility of breast-conserving surgery in selected patients with breast carcinoma. Treatment response, especially complete response, remained the most important factor guiding conservative surgical management. Careful patient selection, response assessment, and multidisciplinary planning may help reduce unnecessary mastectomy while maintaining oncological safety.
Keywords: Breast Carcinoma; Breast-Conserving Surgery; Clinical Stage; Mastectomy; Neoadjuvant Chemotherapy; Surgical De-escalation; Treatment Response.
References
Shang, C. and D. Xu, Epidemiology of Breast Cancer. Oncologie (Tech Science Press), 2022. 24(4).
Gu, H., et al., Global burden and trends of breast cancer: GLOBOCAN 2022 estimates of incidence and mortality in 185 countries. Chinese Medical Journal, 2026. 139(03): p. 404-414.
Freihat, O., D. Sipos, and A. Kovacs, Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data. Frontiers in Public Health, 2025. 13: p. 1622954.
Nikam, P., H.C. Pant, and S. Jabi, An Analysis of the Relationship between Urbanization and the Rise in Cases of Breast Cancer and Its Risk Factors. Journal of Chemical Health Risks, 2026. 16(1): p. 2444.
Ahmad, T., et al., BREAST CANCER IS THE MOST COMMON CANCER IN WOMEN.
Bland, K.I., et al., The breast-E-Book: Comprehensive management of benign and malignant diseases. 2023: Elsevier Health Sciences.
Karadeniz Cakmak, G., Innovative standards in oncoplastic breast conserving surgery: from radical mastectomy to extreme oncoplasty. Breast Care, 2021. 16(6): p. 559-573.
Diao, K., et al., Patient-reported quality of life after breast-conserving surgery with radiotherapy versus mastectomy and reconstruction. Annals of surgery, 2023. 278(5): p. e1096-e1102.
Yao, L., et al., Breast cancer patients: who would benefit from neoadjuvant chemotherapies? Current Oncology, 2022. 29(7): p. 4902-4913.
Hirmas, N., J. Holtschmidt, and S. Loibl, Shifting the paradigm: the transformative role of neoadjuvant therapy in early breast cancer. Cancers, 2024. 16(18): p. 3236.
Sharaf, B., et al., De-escalating breast and axillary surgery in breast cancer: evidence, controversies, and future directions. Frontiers in Oncology, 2026. 16: p. 1717340.
Grigore, R., et al., Impact of oncological treatment on quality of life in patients with head and neck malignancies: a systematic literature review (2020–2025). Current Oncology, 2025. 32(7): p. 379.
Qin, R., et al., Survival Outcomes of Breast-Conserving Surgery Versus Mastectomy in Locally Advanced Breast Cancer Following Neoadjuvant Chemotherapy: A Meta-Analysis. Technology in Cancer Research & Treatment, 2024. 23: p. 15330338241265030.
Golshan, M., et al., Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA surgery, 2020. 155(3): p. e195410.
Wazir, U. and K. Mokbel, De-escalation of breast cancer surgery following neoadjuvant systemic therapy. European journal of breast health, 2021. 18(1): p. 6.
He, X., et al., Long-term overall survival of patients who undergo breast-conserving therapy or mastectomy for early operable HER2-Positive breast cancer after preoperative systemic therapy: an observational cohort study. The Lancet Regional Health–Americas, 2024. 32.
Mohamedahmed, A.Y.Y., et al., Comparison of surgical and oncological outcomes between oncoplastic breast-conserving surgery versus conventional breast-conserving surgery for treatment of breast cancer: a systematic review and meta-analysis of 31 studies. Surgical oncology, 2022. 42: p. 101779.
Franceschini, G., E. Di Guglielmo, and R. Masetti, De-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer patients. Clinical and Experimental Obstetrics & Gynecology, 2024. 51(5): p. 107.
Tesch, M.E. and A.H. Partridge, Treatment of breast cancer in young adults. American Society of Clinical Oncology Educational Book, 2022.
Cathcart-Rake, E.J., et al., Breast cancer in adolescent and young adult women under the age of 40 years. JCO oncology practice, 2021. 17(6): p. 305-313.
Sadasivudu, V., et al., Axillary Response to Neoadjuvant Chemotherapy: Expanding the Scope for Conservative Surgical Management. Indian Journal of Surgical Oncology, 2026: p. 1-8.
Gunasagran, Y. and K. Lim, Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery. Cureus, 2026. 18(1).
Zhang, L., et al., The impact of body mass index on the treatment response to neoadjuvant chemotherapy in patients with breast cancer: A systematic review and meta-analysis. Tumori Journal, 2026. 112(2): p. 102-117.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dr. Zufishan Ahmad, Dr. Irum Sabir Ali, Dr. Mah Muneer Khan (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
